| St Regis Mohawk Health Services | |
|
412 State Route 37 Akwesasne NY 13655-3109 | |
| (518) 358-3141 | |
| (518) 358-2797 |
| Full Name | St Regis Mohawk Health Services |
|---|---|
| Speciality | Clinic/Center |
| Location | 412 State Route 37, Akwesasne, New York |
| Authorized Official Name and Position | Barbara Lazore (TRIBAL CHIEF) |
| Authorized Official Contact | 5183583141 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| St Regis Mohawk Health Services 412 State Route 37 Akwesasne NY 13655-3109 Ph: (518) 358-3141 | St Regis Mohawk Health Services 412 State Route 37 Akwesasne NY 13655-3109 Ph: (518) 358-3141 |
| NPI Number | 1457344558 |
|---|---|
| Provider Enumeration Date | 08/24/2005 |
| Last Update Date | 08/22/2020 |
| Medicare PECOS PAC ID | 5799748547 |
|---|---|
| Medicare Enrollment ID | O20041111000764 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457344558 | NPI | - | NPPES |
| 01178234 | Medicaid | NY | |
| 00651785 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | 1653200R (New York) | Primary |
| Provider Name | Jeffrey M Greenberg |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1902003205 PECOS PAC ID: 5799677191 Enrollment ID: I20040329001548 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Gerald R Lauzon |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1588624720 PECOS PAC ID: 1850385444 Enrollment ID: I20040414001579 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | William R Latreille |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1508885716 PECOS PAC ID: 4284696170 Enrollment ID: I20041102001106 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Robert J Wolff |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1972606234 PECOS PAC ID: 7911960794 Enrollment ID: I20041111000898 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Mary R Mcgonagle |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528091436 PECOS PAC ID: 5890792873 Enrollment ID: I20061106000126 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Stephanie Leffler |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336179365 PECOS PAC ID: 9436254927 Enrollment ID: I20070411000244 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Debra A Meness |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1538195433 PECOS PAC ID: 1153213574 Enrollment ID: I20101013000203 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Wendy L Frank |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1699087171 PECOS PAC ID: 7618149915 Enrollment ID: I20111011000013 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Benson J Kelly |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1487614020 PECOS PAC ID: 2264337658 Enrollment ID: I20111219000202 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Rita E Curran |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1982042370 PECOS PAC ID: 9335383355 Enrollment ID: I20130913000003 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Derek J Reynolds |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285074054 PECOS PAC ID: 4183851199 Enrollment ID: I20131219001442 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Joseph E Robinson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1508946443 PECOS PAC ID: 2466407549 Enrollment ID: I20160825002625 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Mara A Bazdaric-russell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1316245236 PECOS PAC ID: 0446539571 Enrollment ID: I20161114001442 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Brandy Baillargeon |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851743124 PECOS PAC ID: 7315227394 Enrollment ID: I20161208001765 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Brian G Cole |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1184678955 PECOS PAC ID: 5496646655 Enrollment ID: I20170112001216 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Song Y Park |
|---|---|
| Provider Type | Practitioner - Dentist |
| Provider Identifiers | NPI Number: 1225486947 PECOS PAC ID: 9739454117 Enrollment ID: I20171011001498 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Heather M Pontius |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1093206732 PECOS PAC ID: 4284989963 Enrollment ID: I20180620003001 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Mary M Herne |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1730675190 PECOS PAC ID: 5092059725 Enrollment ID: I20181206000364 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Daniel M Cahill |
|---|---|
| Provider Type | Practitioner - Dentist |
| Provider Identifiers | NPI Number: 1770658692 PECOS PAC ID: 1557669579 Enrollment ID: I20190325002613 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Wahienhawi Hall |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1346500345 PECOS PAC ID: 6901228329 Enrollment ID: I20200611003064 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Mary F Krawczewicz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1063955227 PECOS PAC ID: 0648519843 Enrollment ID: I20201218001342 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Christine Venery |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1790849800 PECOS PAC ID: 6709009368 Enrollment ID: I20210105000082 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Joseph S Park |
|---|---|
| Provider Type | Practitioner - Dentist |
| Provider Identifiers | NPI Number: 1396736989 PECOS PAC ID: 6709106529 Enrollment ID: I20210716000442 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Stefanie K Davis |
|---|---|
| Provider Type | Practitioner - Dentist |
| Provider Identifiers | NPI Number: 1922636992 PECOS PAC ID: 9335531615 Enrollment ID: I20220118002133 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Lindsey N Hunter |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1225388234 PECOS PAC ID: 3779950431 Enrollment ID: I20221109001627 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Samanthe A Caza |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1750030672 PECOS PAC ID: 7719356047 Enrollment ID: I20221208002373 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
| Provider Name | Zenas Kuate Defo |
|---|---|
| Provider Type | Practitioner - Dentist |
| Provider Identifiers | NPI Number: 1801479514 PECOS PAC ID: 9335518281 Enrollment ID: I20221215001067 |
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago
News Archive
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
About 300 000 years ago humans adapted genetically to be able to produce larger amounts of Omega-3 and Omega-6 fatty acids. This adaptation may have been crucial to the development of the unique brain capacity in modern humans. In today's life situation, this genetic adaptation contributes instead to a higher risk of developing disorders like cardiovascular disease.
CSL Behring announced today it has been granted national marketing authorization in Israel to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. With this most recent approval, Berinert is now licensed in 30 countries, including Europe, Japan, North America, South America and Australia.
A better understanding of how a key chemical messenger acts in the brain could lead to a radical shift in psychiatric care, according to a new research paper.
› Verified 4 days ago